Q4 2025 13F Holders as of 31 Dec 2025
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
22,926,692
-
Total 13F shares
-
624,377
-
Share change
-
+147,155
-
Total reported value
-
$5,269,801
-
Price per share
-
$8.44
-
Number of holders
-
14
-
Value change
-
+$1,242,802
-
Number of buys
-
6
-
Number of sells
-
4
Institutional Holders of Kalaris Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KLRS) as of Q4 2025
As of 31 Dec 2025,
Kalaris Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KLRS) was held by
14 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
624,377 shares.
The largest 10 holders included
VANGUARD GROUP INC, WHI TRUST Co LLC, GEODE CAPITAL MANAGEMENT, LLC, Fortis Capital Advisors, LLC, Belpointe Asset Management LLC, GOLDMAN SACHS GROUP INC, Simplify Asset Management Inc., Connor, Clark & Lunn Investment Management Ltd., NANO CAP NEW MILLENNIUM GROWTH FUND L P, and UBS Group AG.
This page lists
14
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.